AEG35156 + cytarabine + idarubicin

AEG35156 + cytarabine + idarubicin is a combination regimen investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML)[1][2][4]. The regimen includes **AEG35156**, a second-generation antisense oligonucleotide targeting **X-linked inhibitor of apoptosis protein (XIAP)**, combined with the chemotherapeutic agents **cytarabine** (a cytosine nucleoside analog) and **idarubicin** (an anthracycline antibiotic). - **AEG35156** inhibits XIAP, which normally suppresses apoptotic cell death by inactivating caspases 3 and 9; inhibition of XIAP sensitizes leukemic cells to apoptosis induced by chemotherapy[1][4]. - **Cytarabine** interferes with DNA synthesis, inducing cytotoxicity in leukemic blasts. - **Idarubicin** intercalates DNA and inhibits topoisomerase II, causing DNA damage and cell death. The combination was evaluated in phase I/II trials, showing that AEG35156 knockdown of XIAP mRNA correlated with improved response rates when added to cytarabine/idarubicin in patients with AML refractory to standard induction regimens[1][2][4].

Other names

XIAP antisense oligonucleotide + cytarabine + idarubicin